Vimta Labs Limited (NSE:VIMTALABS)
India · Delayed Price · Currency is INR | Market Cap | 26.68B -24.6% |
| Revenue (ttm) | 4.21B +14.4% |
| Net Income | 796.60M +8.6% |
| EPS | 17.65 +8.4% |
| Shares Out | n/a |
| PE Ratio | 33.49 |
| Forward PE | n/a |
| Dividend | 2.00 (0.32%) |
| Ex-Dividend Date | Jun 18, 2026 |
| Volume | 164,799 |
| Open | 595.25 |
| Previous Close | 598.45 |
| Day's Range | 595.25 - 617.95 |
| 52-Week Range | 376.05 - 851.00 |
| Beta | -0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2026 |
About Vimta Labs
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufactu... [Read more]
Financial Performance
In fiscal year 2026, Vimta Labs's revenue was 4.10 billion, an increase of 18.62% compared to the previous year's 3.45 billion. Earnings were 775.12 million, an increase of 15.10%.
Financial StatementsNews
Vimta Labs Transcript: Q1 26/27
Q1 FY 2027 saw 13.7% year-on-year revenue growth, strong pharma and clinical research performance, and stable margins despite global headwinds. Biologics commercialization began, with exports at 40% of revenue and robust cash reserves supporting disciplined CapEx.
Vimta Labs Quarterly report: Q1 2027
Vimta Labs has published its Q1 2027 quarterly earnings report on July 20, 2026.
Vimta Labs Slides: Q1 2027
Vimta Labs has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 20, 2026.
Vimta Labs pays Rs 2 dividend per share for FY 2025-26
Vimta Labs has announced the payment of a dividend of ₹2 per equity share for the financial year 2025-26. The dividend was approved by shareholders at the company's Annual General…
Vimta Labs Transcript: Q4 25/26
FY 2026 delivered robust growth in core pharma and food testing, with EBITDA margins among the industry's best and a net debt-free balance sheet. Strategic entry into biologics and a new U.S. subsidiary position the company for future expansion, despite global uncertainties.
Vimta Labs Quarterly report: Q4 2026
Vimta Labs has published its Q4 2026 quarterly earnings report on May 30, 2026.
Vimta Labs Slides: Q4 2026
Vimta Labs has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 30, 2026.
Vimta Labs Annual report: Q4 2026
Vimta Labs has published its Q4 2026 annual report on May 30, 2026.
Vimta Labs Transcript: Q3 25/26
Q3 FY26 revenue grew 10.2% year-over-year, led by pharma and food testing, though operational delays deferred some revenue. Nine-month EBITDA margin was 35.1%, with exports rising to 39% of income. Biologics services launch in Q1 FY27, and Q4 is expected to be seasonally strong.
Vimta Labs Quarterly report: Q3 2026
Vimta Labs has published its Q3 2026 quarterly earnings report on January 28, 2026.
Vimta Labs Slides: Q3 2026
Vimta Labs has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 28, 2026.
Vimta Labs Transcript: Q2 25/26
Record Q2 FY26 revenue and profit growth were driven by pharma and food testing, with strong margins and a net debt-free position. Capacity expansions and CapEx support future growth, especially in biologics, while both domestic and export markets contribute to momentum.
Vimta Labs Quarterly report: Q2 2026
Vimta Labs has published its Q2 2026 quarterly earnings report on November 3, 2025.
Vimta Labs Slides: Q2 2026
Vimta Labs has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 3, 2025.
Vimta Labs shares hit fresh all-time high, surges 7%
Vimta Labs, a small-cap player in the healthcare services sector, witnessed a strong rally in Friday’s session, jumping 7.18% to hit a new 52-week high of ₹856.40. The stock registered an intraday inc...
Vimta Labs shares surge 7%, hit fresh 52-week high amid heavy trading volumes
Vimta Labs shares soared 7% in early trade today, reaching a new 52-week high of ₹828.90 amid robust market activity. The stock opened at ₹792.10 and gained steadily from the previous close of ₹763.90...
Stocks to watch on April 29: Wipro, UCO Bank, Central Bank of India, Go Digit, Avenue Supermarts, Oberoi Realty, Ultratech, Vimta Labs, RBL Bank
The Indian stock market is likely to react to a host of corporate earnings, operational updates, and sector developments on Monday, April 29. Companies such as UCO Bank, Central Bank of India, Go Digi...
Vimta Labs Q4 FY25 profit rises 31% YoY; announces 1:1 bonus issue and new biologics R&D foray
Vimta Labs Limited reported robust financial results for the fourth quarter and financial year ended March 31, 2025, backed by strong growth in its pharmaceutical services business. Financial highligh...
Vimta Labs shares surge 34% in past one month
Vimta Labs has been a standout performer in the stock market, with its shares surging 34% over the past month. The stock hit a 52-week high of ₹980.75 on December 6, 2024, reflecting strong investor i...